Aiming for Q2 2012 Launch, GnuBio Builds Beta Version of Microfluidics-Based Sequencing System | GenomeWeb

By Monica Heger

GnuBio said this week that it has begun building the beta version of its microfluidics-based sequencing system and is transitioning into the commercial phase of its business.

Sepehr Kiani, executive vice president of product development, said in a statement that the company routinely gets "600-base reads at 95 percent read yield" with a per-base accuracy "greater than 99.7 percent," and that it can sequence through homopolymers and simple repeat reads of nine bases.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."